LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Lantheus Holdings Inc

Suletud

SektorTervishoid

100.12 0.17

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

97.75

Max

102.44

Põhinäitajad

By Trading Economics

Sissetulek

64M

118M

Müük

-29M

377M

P/E

Sektori keskmine

23.869

49.052

Aktsiakasum

1.46

Kasumimarginaal

31.383

Töötajad

1,193

EBITDA

-17M

81M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+6.02% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2026

Turustatistika

By TradingEconomics

Turukapital

797M

6.5B

Eelmine avamishind

99.95

Eelmine sulgemishind

100.12

Uudiste sentiment

By Acuity

2%

98%

1 / 344 Pingereas Healthcare

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuni 2026, 23:36 UTC

Tulu

Correction to Oracle Reports Higher 4Q Profit Article

10. juuni 2026, 23:19 UTC

Kuumad aktsiad

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10. juuni 2026, 23:09 UTC

Suurimad hinnamuutused turgudel

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10. juuni 2026, 23:04 UTC

Tulu

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10. juuni 2026, 20:44 UTC

Suurimad hinnamuutused turgudel

Caterpillar Raises Quarterly Dividend 8%

10. juuni 2026, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Should Take No Options Off The Table

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10. juuni 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10. juuni 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10. juuni 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10. juuni 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10. juuni 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. juuni 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10. juuni 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10. juuni 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10. juuni 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10. juuni 2026, 21:57 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 21:52 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 21:35 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 21:22 UTC

Tulu

Oracle Stock Slides on Increased Capital Spending -- WSJ

10. juuni 2026, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

10. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. juuni 2026, 20:39 UTC

Market Talk
Tulu

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10. juuni 2026, 20:34 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 20:33 UTC

Tulu

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

6.02% tõus

12 kuu keskmine prognoos

Keskmine 106 USD  6.02%

Kõrge 115 USD

Madal 94 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

7

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

1 / 344 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
help-icon Live chat